Advances in Cancer Research
- 1st Edition, Volume 160 - August 31, 2023
- Editors: Paul B. Fisher, Kenneth D. Tew
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 1 9 2 8 0 - 7
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 9 2 8 1 - 4
Advances in Cancer Research, Volume 160, the latest release in this ongoing, well-regarded serial, provides invaluable information on the exciting and fast-moving field of cancer… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteAdvances in Cancer Research, Volume 160, the latest release in this ongoing, well-regarded serial, provides invaluable information on the exciting and fast-moving field of cancer research, with this updated edition covering PFKP: More Than Phosphofructokinase, Setting sail: maneuvering SHP2 activity and its effects in cancer, Mechanical factors driving cancer progression, Microsomal Glutathione Transferase 1 in Cancer and the Regulation of Ferroptosis, Lnc-ing epigenetic mechanisms with autophagy and cancer drug resistance, Head and Neck Cancer Treatment in the Era of Molecular Medicine, Applications of Tissue-Specific and Cancer-Selective Gene Promoters for Cancer Diagnosis and Therapy, and more.
- Provides the latest information on cancer research
- Offers outstanding and original reviews on a range of cancer research topics
- Serves as an indispensable reference for researchers and students alike
Researchers and students in the basic and clinical sciences of cancer biology and oncology, plus related areas in genetics, immunology, pharmacology, cell biology, and molecular biology
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Chapter One: PFKP: More than phosphofructokinase
- Abstract
- 1 Introduction
- 2 Biological functions of PFKP
- 3 PFKP functions at various cellular locations
- 4 PFKP in immune cells
- 5 The regulation of PFKP expression
- 6 The regulation of PFKP activity
- 7 Prognostic value of PFKP and strategies to target PFKP for cancer therapy
- 8 Conclusion and future directions
- Acknowledgments
- References
- Chapter Two: Setting sail: Maneuvering SHP2 activity and its effects in cancer
- Abstract
- 1 Introduction
- 2 SHP2 in cellular signaling
- 3 SHP2 expression, localization and interacting proteins
- 4 SHP2 in developmental defects and cancer
- 5 SHP2 domain organization and structural properties
- 6 SHP2 allostery
- 7 SHP2 inhibitors
- 8 Conclusions
- References
- Chapter Three: Mechanical factors driving cancer progression
- Abstract
- 1 Introduction
- 2 Tumor microenvironment mechanical factors
- 3 Cellular mechanical factors
- 4 Models to study mechanical regulation of collective invasion
- References
- Chapter Four: Protein disulfide isomerase family mediated redox regulation in cancer
- Abstract
- 1 Introduction
- 2 Classification and Structure of PDI
- 3 Redox regulation: Thiol–disulfide exchange and PDI
- 4 Redox regulation: S-Glutathionylation of redox active cysteines as a protective and regulatory mechanism
- 5 PDI in ER stress and cancer
- 6 PDI and cancers
- 7 PDI inhibitors
- 8 Conclusions
- References
- Chapter Five: Microsomal glutathione transferase 1 in cancer and the regulation of ferroptosis
- Abstract
- 1 Introduction
- 2 Subcellular distribution of MGST1
- 3 MGST1 activation
- 4 MGST1 induction
- 5 MGST1 in apoptosis
- 6 MGST1 in ferroptosis
- 7 MGST1 in cancer
- 8 Summary
- Acknowledgment
- References
- Chapter Six: Lnc-ing epigenetic mechanisms with autophagy and cancer drug resistance
- Abstract
- Abbreviations
- 1 Introduction
- 2 Cell death pathway and cancer drug resistance
- 3 Autophagy: In the context of cancer and cancer drug resistance
- 4 LncRNA mediated cancer drug resistance: The autophagic axis
- 5 LncRNA targeted cancer therapy
- 6 Conclusion and future perspectives
- Acknowledgments
- References
- Chapter Seven: Head and neck cancer treatment in the era of molecular medicine
- Abstract
- Abbreviations
- 1 Background
- 2 Epidemiology of HNSCC
- 3 The complex biology of HNSCC
- 4 Conclusions
- References
- Chapter Eight: Applications of tissue-specific and cancer-selective gene promoters for cancer diagnosis and therapy
- Abstract
- Abbreviation
- 1 Introduction
- 2 Strategies to accomplish targeted expression of transgenes in cancer using different promoter systems
- 3 Vectors used for the delivery of promoters for cancer therapy
- 4 Most commonly used promoters to target cancers
- 5 Most common cancers being treated with specific promoters
- 6 Promoters used for the molecular imaging of cancers
- 7 Augmenting cancer-specific expression
- 8 Applications of omics approaches to identify and develop future novel promoter-based therapeutics
- 9 Conclusions
- Acknowledgements
- References
- No. of pages: 330
- Language: English
- Edition: 1
- Volume: 160
- Published: August 31, 2023
- Imprint: Academic Press
- Hardback ISBN: 9780443192807
- eBook ISBN: 9780443192814
PF
Paul B. Fisher
Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 625 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based company (at Johns Hopkins Medical Center) focusing on imaging and therapy (“theranostics”) of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018).
Affiliations and expertise
Department of Human and Molecular Genetics, VCU Institute of Molecular Medicine, VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Virginia, USAKT
Kenneth D. Tew
Professor & Chairman, Dept of Cell & Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USA
The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.
Affiliations and expertise
Professor and Chairman, Department of Cell and Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USARead Advances in Cancer Research on ScienceDirect